Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth

Thrombospondin‐1 (TSP‐1) is a matricellular glycoprotein that influences cellular phenotype and the structure of the extracellular matrix. These effects are important components of the tissue remodeling that is associated with angiogenesis and neoplasia. The genetic mutations in oncogenes and tumor suppressor genes that occur within tumor cells are frequently associated with decreased expression of TSP‐1. However, the TSP‐1 that is produced by stromal fibroblasts, endothelial cells and immune cells suppresses tumor progression. TSP‐1 inhibits angiogenesis through direct effects on endothelial cell migration and survival and through indirect effects on growth factor mobilization. TSP‐1 that is present in the tumor microenvironment also acts to suppress tumor cell growth through activation of transforming growth factor β in those tumor cells that are responsive to TGFβ. In this review, the molecular basis for the role of TSP‐1 in the inhibition of tumor growth and angiogenesis is summarized.

[1]  M. Detmar,et al.  Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Westrick,et al.  Incorporation of thrombospondin into fibrin clots. , 1985, The Journal of biological chemistry.

[3]  H. Krutzsch,et al.  Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. , 1999, The Journal of biological chemistry.

[4]  B. Griffin,et al.  Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. , 1993, Investigative ophthalmology & visual science.

[5]  D. Mosher,et al.  Interaction of Recombinant Procollagen and Properdin Modules of Thrombospondin-1 with Heparin and Fibrinogen/Fibrin* , 1999, The Journal of Biological Chemistry.

[6]  H. Krutzsch,et al.  Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. , 1997, Cancer research.

[7]  J. Lawler,et al.  Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. , 2001, Cancer research.

[8]  K. Skorstengaard,et al.  Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondin , 1992, The Journal of cell biology.

[9]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[10]  G. Burns,et al.  The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. , 2000, The Journal of biological chemistry.

[11]  H. Fillit,et al.  Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1. , 2000, Archives of biochemistry and biophysics.

[12]  Erwin G. Van Meir,et al.  Thrombospondin-1 Is Downregulated by Anoxia and Suppresses Tumorigenicity of Human Glioblastoma Cells , 2000, The Journal of experimental medicine.

[13]  R. Hynes,et al.  Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.

[14]  P. L.,et al.  Diversity of Function Is Inherent in Matricellular Proteins : An Appraisal of Thrombospondin I , 2002 .

[15]  D. Mosher,et al.  Calcium Ion Binding to Thrombospondin 1 (*) , 1995, The Journal of Biological Chemistry.

[16]  E. Brown,et al.  Thrombospondin Modulates OLv ~ 3 Function through Integrin-associated Protein , 2002 .

[17]  R. Kerbel.  A cancer therapy resistant to resistance , 1997, Nature.

[18]  C. Sevignani,et al.  Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. , 2000, Nucleic acids research.

[19]  N. Fusenig,et al.  Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Murphy-Ullrich,et al.  Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology , 2000 .

[21]  R. Hynes,et al.  The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins , 1986, The Journal of cell biology.

[22]  O. Volpert,et al.  Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. , 1999, Molecular pharmacology.

[23]  E. Brown,et al.  Role of Cholesterol in Formation and Function of a Signaling Complex Involving αvβ3, Integrin-Associated Protein (Cd47), and Heterotrimeric G Proteins , 1999, The Journal of cell biology.

[24]  M. Karin,et al.  c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1 , 2001, Oncogene.

[25]  H. Krutzsch,et al.  Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin‐binding domain and synthetic peptides from the type I repeats of thrombospondin , 1993, Journal of cellular biochemistry.

[26]  S. Schultz-Cherry,et al.  The Activation Sequence of Thrombospondin-1 Interacts with the Latency-associated Peptide to Regulate Activation of Latent Transforming Growth Factor-β* , 1999, The Journal of Biological Chemistry.

[27]  D. Mooney,et al.  Thrombospondin-1 Induces Endothelial Cell Apoptosis and Inhibits Angiogenesis by Activating the Caspase Death Pathway , 2000, Journal of Vascular Research.

[28]  William Arbuthnot Sir Lane,et al.  CD36 associates with CD9 and integrins on human blood platelets. , 2001, Blood.

[29]  B. Maček,et al.  C-Mannosylation and O-Fucosylation of the Thrombospondin Type 1 Module* , 2001, The Journal of Biological Chemistry.

[30]  Josephine C. Adams,et al.  The thrombospondin type 1 repeat (TSR) superfamily: Diverse proteins with related roles in neuronal development , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[31]  D. Roberts,et al.  Pro-adhesive and Chemotactic Activities of Thrombospondin-1 for Breast Carcinoma Cells Are Mediated by α3β1 Integrin and Regulated by Insulin-like Growth Factor-1 and CD98* , 1999, The Journal of Biological Chemistry.

[32]  E. Ginns,et al.  Mice That Lack Thrombospondin 2 Display Connective Tissue Abnormalities That Are Associated with Disordered Collagen Fibrillogenesis, an Increased Vascular Density, and a Bleeding Diathesis , 1998, The Journal of cell biology.

[33]  H. Granger,et al.  The heparin binding 25 kDa fragment of thrombospondin‐1 promotes angiogenesis and modulates gelatinase and TIMP‐2 production in endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  P. Bornstein,et al.  The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun , 1999, Oncogene.

[35]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[36]  A. Ludlow,et al.  Activation of Platelet-transforming Growth Factor β-1 in the Absence of Thrombospondin-1* , 2000, The Journal of Biological Chemistry.

[37]  Anthony J. Guidi,et al.  Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  E. Biganzoli,et al.  Thrombospondin-1 and -2 in Node-Negative Breast Cancer: Correlation with Angiogenic Factors, p53, Cathepsin D, Hormone Receptors and Prognosis , 2000, Oncology.

[39]  J. Lawler,et al.  The cell biology of thrombospondin-1. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[40]  Erwin G. Van Meir,et al.  Thrombospondins and tumor angiogenesis. , 2001, Trends in molecular medicine.

[41]  Thrombospondin 1 does not activate transforming growth factor beta1 in a chemically defined system or in smooth-muscle-cell cultures. , 2000, The Biochemical journal.

[42]  Y. Fukushima,et al.  Alterations in tumour suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells , 1998, Virchows Archiv.

[43]  E. Chambaz,et al.  Analysis of small latent transforming growth factor-beta complex formation and dissociation by surface plasmon resonance. Absence of direct interaction with thrombospondins. , 1997, The Journal of biological chemistry.

[44]  E. Brown,et al.  Integrin-associated Protein Is a Receptor for the C-terminal Domain of Thrombospondin (*) , 1996, The Journal of Biological Chemistry.

[45]  E. Brown,et al.  Thrombospondin modulates alpha v beta 3 function through integrin- associated protein , 1996, The Journal of cell biology.

[46]  G. Tuszynski,et al.  Matrix-bound thrombospondin promotes angiogenesis in vitro , 1994, The Journal of cell biology.

[47]  O. Volpert,et al.  In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. , 2001, Genes & development.

[48]  M. Iruela-Arispe,et al.  Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. , 1999, Circulation.

[49]  H. Krutzsch,et al.  Regulation of Transforming Growth Factor-β Activation by Discrete Sequences of Thrombospondin 1 (*) , 1995, The Journal of Biological Chemistry.

[50]  J. Lawler,et al.  Cooperative binding of calcium to thrombospondin. The effect of calcium on the circular dichroism and limited tryptic digestion of thrombospondin. , 1983, The Journal of biological chemistry.

[51]  T. Kurosaki,et al.  Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. , 1998, Cancer detection and prevention.

[52]  S. Wada,et al.  Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival. , 2000, Oral oncology.

[53]  P. Bornstein,et al.  Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Aeschlimann,et al.  Expression and initial characterization of recombinant mouse thrombospondin 1 and thrombospondin 3 , 1996, FEBS letters.

[55]  J. Lawler.  The functions of thrombospondin-1 and-2. , 2000, Current opinion in cell biology.

[56]  R. Hynes,et al.  Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. , 2001, The American journal of pathology.

[57]  T. Mikkelsen,et al.  Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. , 1996, Cancer research.

[58]  O. Volpert,et al.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.

[59]  C. Meldrum,et al.  Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. , 1996, The Biochemical journal.

[60]  J. Connolly,et al.  The structure of human platelet thrombospondin. , 1985, The Journal of biological chemistry.

[61]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[62]  G. Burns,et al.  The Integrins α3β1and α6β1Physically and Functionally Associate with CD36 in Human Melanoma Cells: REQUIREMENT FOR THE EXTRACELLULAR DOMAIN OF CD36 , 2000 .

[63]  H. Krutzsch,et al.  Identification of an α3β1 Integrin Recognition Sequence in Thrombospondin-1* , 1999, The Journal of Biological Chemistry.

[64]  O. Volpert,et al.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.

[65]  S. Groshen,et al.  Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.

[66]  P. Bork,et al.  Merging extracellular domains: fold prediction for laminin G-like and amino-terminal thrombospondin-like modules based on homology to pentraxins. , 1998, Journal of molecular biology.

[67]  H. Krutzsch,et al.  Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[68]  N. Bertin,et al.  Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. , 1997, Cancer research.

[69]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.

[70]  J. Murphy-Ullrich,et al.  Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. , 2000, Cytokine & growth factor reviews.

[71]  P. Delmas,et al.  Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. , 1993, Cancer research.

[72]  R. Hynes,et al.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.